Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Download PDF
May 3, 2016
/
News
Share
the Post
Related
Posts
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Support letter for inclusion of Daclatasvir on 4th March, 2015.
Part 1: What is hepatitis C and how is it diagnosed?
Generic daclatasvir (60 mg) availability and India market pricing as of 30 January 2016
Updated Generic Sofosbuvir Availability and Price in India 15 June 2015
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation
Four Indian generic companies take sub license from MPP on daclatasvir
